A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Conditions: Neoplasms; Melanoma; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamous Cell Carcinoma (HNSCC); Renal Cell Carcinoma (RCC); Urothelial Neoplasm; Hepatocellular Carcinoma (HCC); Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR); Colorectal Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Cancer; Cervical Cancer; Primary Peritoneal Cancer; Platinum-resistant Ovarian Cancer (PROC); Serous Epithelial Ovarian Cancer; Fallopian Tube Cancer
Interventions: Drug: DSP-7888 Dosing Emulsion; Drug: Nivolumab; Drug: Pembrolizumab
Sponsor: Boston Biomedical, Inc
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.